Cargando…
SARS-CoV-2: Origin, Evolution, and Targeting Inhibition
Severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) caused an outbreak in Wuhan city, China and quickly spread worldwide. Currently, there are no specific drugs or antibodies that claim to cure severe acute respiratory diseases. For SARS-CoV-2, the spike (S) protein recognizes and binds to...
Autores principales: | Ning, Shuo, Yu, Beiming, Wang, Yanfeng, Wang, Feng |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Frontiers Media S.A.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8248807/ https://www.ncbi.nlm.nih.gov/pubmed/34222046 http://dx.doi.org/10.3389/fcimb.2021.676451 |
Ejemplares similares
-
Drug-induced phospholipidosis is not correlated with the inhibition of SARS-CoV-2 - inhibition of SARS-CoV-2 is cell line-specific
por: Diesendorf, Viktoria, et al.
Publicado: (2023) -
Integrins as Therapeutic Targets for SARS-CoV-2
por: Gressett, Timothy E., et al.
Publicado: (2022) -
Unraveling the Epidemiology, Geographical Distribution, and Genomic Evolution of Potentially Lethal Coronaviruses (SARS, MERS, and SARS CoV-2)
por: Masood, Nosheen, et al.
Publicado: (2020) -
Perspectives: SARS-CoV-2 Spike Convergent Evolution as a Guide to Explore Adaptive Advantage
por: Zahradník, Jiri, et al.
Publicado: (2022) -
Pre-existing anti-HCoV-OC43 immunity influences the durability and cross-reactivity of humoral response to SARS-CoV-2 vaccination
por: Hu, Caiqin, et al.
Publicado: (2022)